Drugs / BAFFR CAR-T
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07196111 | Oct 2025 → Oct 2028 | B-cell acute lymphoblastic leukemia | Guangzhou Bio-gene Technology Co., Ltd | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07259070 | Nov 2025 → Nov 2029 expected | B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma, marginal zone lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07022197 | Apr 2025 → Dec 2027 expected | chronic inflammatory demyelinating polyradiculoneuropathy, idiopathic inflammatory myopathy, myasthenia gravis, neuromyelitis optica | Tianjin Medical University General Hospital | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07345728 | Jan 2026 → Jun 2029 expected | B-cell neoplasm | Donghua Zhang | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAFFR CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07345728 ↗ |
| Action | Deplete | “Characteristics of BAFF-R+ B cell and antibody secreting cell (ASC) lymphocyte ablation in subjects” NCT07022197 ↗ |
| Modality | Cell therapy | “autologous T cells expressing chimeric antigen receptor (CAR)-targeted B-cell activating factor receptor (BAFFR)” NCT07022197 ↗ |
| Route | Intravenous | “by intravenous (IV) infusion” NCT07022197 ↗ |